Related references
Note: Only part of the references are listed.Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
B. J. Monk et al.
ANNALS OF ONCOLOGY (2015)
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies
Margaret von Mehren et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
B. Bui-Nguyen et al.
EUROPEAN JOURNAL OF CANCER (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
Akira Kawai et al.
LANCET ONCOLOGY (2015)
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
Axel Le Cesne et al.
LANCET ONCOLOGY (2015)
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Patricia Pautier et al.
LANCET ONCOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
S. Delaloge et al.
ANNALS OF ONCOLOGY (2014)
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens
Lori J. Goldstein et al.
CLINICAL BREAST CANCER (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Mode of action of trabectedin in myxoid liposarcomas
S. Di Giandomenico et al.
ONCOGENE (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Analysis of DNA Repair-Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
Maria J. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells
Harika Atmaca et al.
TOXICOLOGY LETTERS (2013)
New activities for the anti-tumor agent trabectedin: taking two birds with one stone
Maurizio D'Incalci et al.
ONCOTARGET (2013)
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
M. D. Michaelson et al.
ANNALS OF ONCOLOGY (2012)
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2012)
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents
S. Uboldi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors
Laura Vidal et al.
INVESTIGATIONAL NEW DRUGS (2012)
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
Luis Paz-Ares et al.
INVESTIGATIONAL NEW DRUGS (2012)
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies
Lia Gore et al.
INVESTIGATIONAL NEW DRUGS (2012)
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
Bartomeu Massuti et al.
LUNG CANCER (2012)
XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids
Sascha Feuerhahn et al.
CHEMISTRY & BIOLOGY (2011)
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2011)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
Quincy Chu et al.
CLINICAL CANCER RESEARCH (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo et al.
ANNALS OF ONCOLOGY (2009)
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Bahram Forouzesh et al.
CLINICAL CANCER RESEARCH (2009)
Phase I clinical and pharmacokinetic study of trablectedin and cisplatin in solid tumours
C. Sessa et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
C. Sessa et al.
EUROPEAN JOURNAL OF CANCER (2009)
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study
D. S. McMeekin et al.
GYNECOLOGIC ONCOLOGY (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Claudia Forni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
M. von Mehren et al.
ANNALS OF ONCOLOGY (2008)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
Wells A. Messersmith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Von Hippel-Lindau - Coupled and Transcription-Coupled Nucleotide Excision Repair - Dependent Degradation of RNA Polymerase 11 in Response to Trabectendin
Gregory J. Aune et al.
CLINICAL CANCER RESEARCH (2008)
Role of homologous recombination in trabectedin-induced DNA damage
M. Tavecchio et al.
EUROPEAN JOURNAL OF CANCER (2008)
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach
M. Tavecchio et al.
CELL PROLIFERATION (2007)
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The apoptosome: signalling platform of cell death
Stefan J. Riedl et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
L. Zelek et al.
BRITISH JOURNAL OF CANCER (2006)
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters
M Minuzzo et al.
MOLECULAR PHARMACOLOGY (2005)
Apoptosis pathways in cancer and cancer therapy
KM Debatin
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma
S Donald et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
C Twelves et al.
EUROPEAN JOURNAL OF CANCER (2003)
Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells - Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis
C Gajate et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
G Damia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
A Taamma et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
S Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
